BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 23192851)

  • 1. Pharmacokinetics of vicagrel, a promising analog of clopidogrel, in rats and beagle dogs.
    Qiu Z; Li N; Wang X; Tian F; Liu Q; Song L; Fan Z; Lu Y; Chen X
    J Pharm Sci; 2013 Feb; 102(2):741-9. PubMed ID: 23192851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a sensitive and rapid UHPLC-MS/MS method for the simultaneous quantification of the common active and inactive metabolites of vicagrel and clopidogrel in human plasma.
    Liu C; Lu Y; Sun H; Yang J; Liu Y; Lai X; Gong Y; Liu X; Li Y; Zhang Y; Chen X; Zhong D
    J Pharm Biomed Anal; 2018 Feb; 149():394-402. PubMed ID: 29154109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming clopidogrel resistance: discovery of vicagrel as a highly potent and orally bioavailable antiplatelet agent.
    Shan J; Zhang B; Zhu Y; Jiao B; Zheng W; Qi X; Gong Y; Yuan F; Lv F; Sun H
    J Med Chem; 2012 Apr; 55(7):3342-52. PubMed ID: 22428882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs.
    Hagihara K; Kazui M; Ikenaga H; Nanba T; Fusegawa K; Takahashi M; Kurihara A; Okazaki O; Farid NA; Ikeda T
    Xenobiotica; 2009 Mar; 39(3):218-26. PubMed ID: 19280520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significant Improvement of Metabolic Characteristics and Bioactivities of Clopidogrel and Analogs by Selective Deuteration.
    Xu X; Zhao X; Yang Z; Wang H; Meng X; Su C; Liu M; Fawcett JP; Yang Y; Gu J
    Molecules; 2016 May; 21(6):. PubMed ID: 27248988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of a UPLC-MS/MS method for simultaneous determination of vicagrel and its major metabolites in rat or human plasma: An optimized novel strategy for the stabilization of vicagrel.
    Tai T; Zhou H; Zhu T; Jia YM; Ji JZ; Li YF; Mi QY; Xie HG
    J Pharm Biomed Anal; 2020 Feb; 179():112955. PubMed ID: 31866139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contributions of intestine and plasma to the presystemic bioconversion of vicagrel, an acetate of clopidogrel.
    Qiu Z; Li N; Song L; Lu Y; Jing J; Parekha HS; Gao W; Tian F; Wang X; Ren S; Chen X
    Pharm Res; 2014 Jan; 31(1):238-51. PubMed ID: 24037619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming Clopidogrel Resistance: Three Promising Novel Antiplatelet Drugs Developed in China.
    Xie HG; Jia YM; Tai T; Ji JZ
    J Cardiovasc Pharmacol; 2017 Dec; 70(6):356-361. PubMed ID: 28817486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impacts of CYP2C19 genetic polymorphisms on bioavailability and effect on platelet adhesion of vicagrel, a novel thienopyridine P2Y
    Zhang Y; Zhu X; Zhan Y; Li X; Liu C; Zhu Y; Zhang H; Wei H; Xia Y; Sun H; Liu Y; Lai X; Gong Y; Liu X; Li Y; Ding Y; Zhong D
    Br J Clin Pharmacol; 2020 Sep; 86(9):1860-1874. PubMed ID: 32267573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Semi-mechanistic population pharmacokinetics analysis reveals distinct CYP2C19 dependency in the bioactivation of vicagrel and clopidogrel to active metabolite M15-2.
    Zhang L; Sun H; Liu Y; Lai X; Gong Y; Liu X; Li YG; He Y; Zhang EY; Yan X
    Eur J Pharm Sci; 2022 Oct; 177():106264. PubMed ID: 35868434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacokinetic/pharmacodynamic relationship of vicagrel, a novel thienopyridine P2Y
    Liu C; Zhang Y; Chen W; Lu Y; Li W; Liu Y; Lai X; Gong Y; Liu X; Li Y; Chen X; Li X; Sun H; Yang J; Zhong D
    Eur J Pharm Sci; 2019 Jan; 127():151-160. PubMed ID: 30326264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Species Comparison of Pre-systemic Bioactivation of Vicagrel, a New Acetate Derivative of Clopidogrel.
    Qiu ZX; Gao WC; Dai Y; Zhou SF; Zhao J; Lu Y; Chen XJ; Li N
    Front Pharmacol; 2016; 7():366. PubMed ID: 27774067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, mass balance, and metabolism of [
    Zheng YD; Zhang H; Zhan Y; Bian YC; Ma S; Gan HX; Lai XJ; Liu YQ; Gong YC; Liu XF; Sun HB; Li YG; Zhong DF; Miao LY; Diao XX
    Acta Pharmacol Sin; 2021 Sep; 42(9):1535-1546. PubMed ID: 33244163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel.
    Hagihara K; Kazui M; Kurihara A; Yoshiike M; Honda K; Okazaki O; Farid NA; Ikeda T
    Drug Metab Dispos; 2009 Nov; 37(11):2145-52. PubMed ID: 19704027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin Attenuates the Bioactivation of and Platelet Response to Vicagrel in Mice.
    Jia YM; Gu TT; Ji JZ; Tai T; Zhang MR; Huang BB; Zhou H; Mi QY; Xie HG
    J Cardiovasc Pharmacol; 2018 Nov; 72(5):252-258. PubMed ID: 30358688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced responsiveness of platelets to vicagrel in IL-10-deficient mice through STAT3-dependent up-regulation of the hydrolase arylacetamide deacetylase in the intestine.
    Jia YM; Zhou H; Tai T; Gu TT; Ji JZ; Mi QY; Huang BB; Li YF; Zhu T; Xie HG
    Br J Pharmacol; 2019 Jun; 176(11):1717-1727. PubMed ID: 30825385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese Volunteers.
    Li X; Liu C; Zhu X; Wei H; Zhang H; Chen H; Chen G; Yang D; Sun H; Shen Z; Zhang Y; Li W; Yang J; Liu Y; Lai X; Gong Y; Liu X; Li Y; Zhong D; Niu J; Liu B; Ding Y
    Front Pharmacol; 2018; 9():643. PubMed ID: 29973877
    [No Abstract]   [Full Text] [Related]  

  • 18. Platelet inhibitory activity, tolerability, and safety of vicagrel, a novel thienopyridine P2Y12 inhibitor.
    Li H; Chen H; Chen W; Xu H; Yuan F; Yang M; Sun H; Yang J; Liu Y; Lai X; Gong Y; Liu X; Li Y; Sheng L; Liu C; Li X
    Medicine (Baltimore); 2020 Jan; 99(4):e18683. PubMed ID: 31977858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic basis of the antiplatelet action of prasugrel.
    Schrör K; Siller-Matula JM; Huber K
    Fundam Clin Pharmacol; 2012 Feb; 26(1):39-46. PubMed ID: 21895761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human Liver Cytochrome P450 Enzymes and Microsomal Thiol Methyltransferase Are Involved in the Stereoselective Formation and Methylation of the Pharmacologically Active Metabolite of Clopidogrel.
    Liu C; Chen Z; Zhong K; Li L; Zhu W; Chen X; Zhong D
    Drug Metab Dispos; 2015 Oct; 43(10):1632-41. PubMed ID: 26220948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.